Dyne Therapeutics, Inc. (NASDAQ: DYN) has reported its financial results for the fourth quarter and full year of 2025, along with recent business highlights. The company's year-end cash position stood at an impressive $1.1 billion, with an expected cash runway into the first quarter of 2028.
In terms of research and development (R&D) expenses, there was a substantial increase from the previous year. R&D expenses were $95.4 million and $81.8 million for the quarters ended December 31, 2025 and 2024, respectively. For the full years ended December 31, 2025 and 2024, R&D expenses were $398.3 million and $281.4 million, respectively.
General and administrative (G&A) expenses also saw an uptick, with expenses amounting to $20.7 million and $15.3 million for the quarters ended December 31, 2025 and 2024, respectively. For the full years ended December 31, 2025 and 2024, G&A expenses were $69.9 million and $62.5 million, respectively.
The net loss for the quarter ended December 31, 2025, was $112.0 million, or $0.76 per basic and diluted share, compared with a net loss of $89.5 million, or $0.88 per basic and diluted share, for the quarter ended December 31, 2024. For the year ended December 31, 2025, the net loss was $446.2 million, or $3.47 per basic and diluted share, as opposed to a net loss of $317.4 million, or $3.37 per basic and diluted share, for the year ended December 31, 2024.
Moving to the company's business highlights, Dyne Therapeutics reported positive topline results from the registrational expansion cohort (REC) of the DELIVER trial of z-rostudirsen in Duchenne muscular dystrophy (DMD). The REC, which included 32 participants, demonstrated a statistically significant change from baseline in muscle content-adjusted dystrophin expression to 5.46% of normal at six months (p<0.0001). Additionally, improvements relative to placebo were observed across all six prespecified topline functional endpoints.
The company also completed enrollment in the registrational expansion cohort of the ACHIEVE trial of z-basivarsen in myotonic dystrophy type 1 (DM1), with the data expected in the second quarter of 2026. Furthermore, Dyne Therapeutics is advancing four development candidates for the potential treatment of DMD amenable to skipping of exons 53, 45, 44, and 55.
Dyne's CEO, John Cox, expressed confidence in the company's progress, stating, "Dyne is entering a critical period of transformation as we advance programs from our clinically validated force platform toward commercialization, with our first potential launch in DMD in less than 12 months, if priority review is granted and approval is received. In 2026, we are focused on disciplined execution across our two lead programs with the goal of delivering potential best-in-class therapies to patients as quickly as possible."
The company's developments and financial position indicate a period of significant advancement and investment in their pipeline, positioning them for potential future growth and success in the treatment of neuromuscular diseases. The market has reacted to these announcements by moving the company's shares 1.74% to a price of $16.705. Check out the company's full 8-K submission here.
